Navigation Links
Iomai Announces Year-End 2007 Financial Results and Business Progress
Date:3/6/2008

d number of shares outstanding as a result of our $30.2 million private placement completed on March 2, 2007. For the fourth quarter of 2007, Iomai's net loss was $6.2 million, or $0.24 loss per share, compared to a net loss in the fourth quarter of 2006 of $9.9 million, or $0.53 loss per share. As of Dec. 31, 2007, Iomai had common stock outstanding of 25,588,673 shares.

The Company reported revenues of $10.7 million for the year ended Dec. 31, 2007, compared to $1.5 million in the year ended Dec. 31, 2006. The increase in revenue in 2007 was principally from the reimbursement of expenses incurred under the DHHS contract. Iomai reported revenues of approximately $3.3 million in the fourth quarter of 2007, compared to approximately $40,000 in the fourth quarter of 2006.

Total operating expenses were $39.8 million in 2007, compared to operating expenses of $33.9 million in 2006. The increase in operating expenses was primarily due to five major factors associated with supporting our development programs: (1) higher payroll and stock compensation costs associated with a 28% increase in full-time employee equivalents, (2) higher facility costs associated with leasing additional space, (3) increased animal study costs associated with work performed under our DHHS contract, (4) higher contract manufacturing costs associated with procuring and finishing the pandemic flu vaccine for the clinical trial under the DHHS contract, and (5) higher consulting costs associated with market studies for our product candidates. These increased costs were partially offset by lower development costs for our skin preparation system.

Total operating costs for the fourth quarter of 2007 were $9.6 million as compared to $10.1 million for the fourth quarter of 2006. The decrease in operating expenses was primarily due to decreased in year-to-year clinical trial costs for Iomai's needle-free travelers' diarrhea vaccine and decreased contract manufacturing expenses.


'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
2. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
3. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
4. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
5. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
6. Dragon announces new product launch; increase in annual production output capacity
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. China Yingxia International Announces Q4 and FY 2007 Estimates
9. Bristol-Myers Squibb Announces Dividend
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
11. Maxygen Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
... Development Efforts, SALT LAKE CITY, Sept. 5 ... development of molecular diagnostic and motion preserving,technologies in ... Ross has,joined the executive management team as the ... this new role, Ross will oversee Axial Biotech,s ...
... Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ZMH ... have,agreed to acquire the Abbott Spine business from Abbott ... to fund the purchase price,from cash on hand and ... expected to close in the fourth quarter of 2008. ...
Cached Biology Technology:Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... discovery of potential environmental and human health effects ... each year has led scientists to recommend stronger ... of lithium-ion (Li-ion) battery materials. That,s the conclusion ... Environmental Science & Technology . , Oladele ... batteries have become mainstays for powering everything from ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... forests that add the most new growth each year -- ... Survey (USGS) study published in a recent issue of the ... forests will respond to ongoing and future environmental changes. , ... world¹s most productive forests may be those likely to respond ...
... DuPont polymer derived from a biological source, has been ... China Central Television (CCTV) as "Most Visionary Innovation" at ... DuPontTM Sorona® will receive the 2005 "New ... Global Plastics and Environmental Conference, sponsored by the Society ...
... core cellular mechanisms of sleep, researchers at University of ... a single gene mutation that has a powerful effect ... In its normal state, the Drosophila (fruit fly) gene, ... flow of potassium into cells, a process that critically ...
Cached Biology News:Live fast, die young true for forests too 2DuPont's first biologically derived polymer receives global recognition 2Wisconsin researchers identify sleep gene 2Wisconsin researchers identify sleep gene 3Wisconsin researchers identify sleep gene 4
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
Biology Products: